Sayin Tamer, Ozenci Metin
Ankara University, Department of Cardiology, Heart Center, Ankara, Turkey.
Acta Cardiol. 2007 Feb;62(1):47-9. doi: 10.2143/AC.62.1.2019370.
Primary pulmonary hypertension is a rare disease with an ominous prognosis for which new therapeutic options are being developed. Recently, there have been case reports indicating that sildenafil may be of benefit in short- to midterm follow-up. However, long-term clinical data of sildenafil in primary pulmonary hypertensive patients is lacking. We report a patient with primary pulmonary hypertension treated with sildenafil 200 mg/day for 50 months with a sustained clinical response.
原发性肺动脉高压是一种预后不佳的罕见疾病，目前正在研发新的治疗方案。最近，有病例报告表明，西地那非在短期至中期随访中可能有益。然而，缺乏西地那非用于原发性肺动脉高压患者的长期临床数据。我们报告了一名原发性肺动脉高压患者，接受每日200毫克西地那非治疗50个月，临床反应持续。
